Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Skye Bioscience, Inc. securities, alleging that the company made materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab, during the class period from November 4, 2024, to October 3, 2025 [1][5]. Group 1: Lawsuit Details - The class action lawsuit has already been filed, and investors who purchased Skye securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - The lawsuit claims that defendants overstated the clinical, regulatory, and commercial prospects of nimacimab, leading to materially false and misleading public statements [5]. Group 2: Participation Information - Investors wishing to join the class action can do so by visiting the Rosen Law Firm's website or contacting their office directly [3][6]. - A lead plaintiff must move the court by January 16, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Insights - Class actions have been initiated on behalf of stockholders of Skye Bioscience, Inc. and Perrigo Company plc, with deadlines for lead plaintiff petitions set for January 16, 2026 [1][3][7]. Perrigo Company plc - The class period for Perrigo is from February 27, 2023 to November 4, 2025, during which the company allegedly failed to disclose significant issues in its infant formula business acquired from Nestlé, including underinvestment and manufacturing deficiencies [3][4]. - On November 5, 2025, Perrigo announced disappointing financial results for Q3 2025, leading to a reduction in its fiscal year 2025 outlook primarily due to challenges in the infant formula industry [4]. - Following the announcement, Perrigo's stock price dropped by $5.09, or 25.2%, closing at $15.10 per share [4]. Skye Bioscience, Inc. - The class period for Skye is from November 4, 2024 to October 3, 2025, during which the company allegedly made materially false statements regarding the effectiveness and prospects of its drug nimacimab [7]. - On October 6, 2025, Skye disclosed that the nimacimab monotherapy did not achieve its primary endpoint in a clinical study, resulting in a stock price decline of $2.85, or 60%, closing at $1.90 per share [7].

Nov 18, 2025 2:54 PM Eastern Standard Time The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit With the Schall Law Firm Share LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights ...

Core Viewpoint - A class action has been filed against Skye Bioscience, Inc. for allegedly misleading investors about the effectiveness and prospects of its lead drug candidate, nimacimab [1][2]. Group 1: Company Overview - Skye Bioscience, Inc. is a clinical stage biopharmaceutical company focused on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases [1]. - The lead product candidate of the company is nimacimab [1]. Group 2: Allegations and Impact - The complaint alleges that during the class period, Skye failed to disclose that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [2]. - On October 6, 2025, Skye announced that the nimacimab monotherapy did not achieve the primary endpoint of weight loss compared to placebo, resulting in a stock price drop of $2.85 per share, or 60%, closing at $1.90 per share [3]. Group 3: Legal Proceedings - Shareholders wishing to serve as lead plaintiff in the class action must submit their papers by January 16, 2026 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against Skye Bioscience, Inc. (NASDAQ: SKYE) on behalf of investors who suffered significant losses during the specified Class Period from November 4, 2024, to October 3, 2025, due to alleged misleading statements regarding the company's business operations [1][3]. Allegations - The lawsuit claims that Skye Bioscience made materially false and misleading statements about its business, specifically regarding the effectiveness of its drug nimacimab, which was overstated, leading to inflated clinical, regulatory, and commercial prospects [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file motions by January 16, 2026, and can choose to remain absent class members without participating in the case [4]. Rosen Law Firm Background - Rosen Law Firm is recognized for its commitment to shareholder rights litigation, having recovered over $1 billion for shareholders since its inception, and operates on a contingency fee basis, meaning shareholders incur no fees or expenses [6].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for alleged violations of federal securities laws during the specified Class Period [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Skye securities between November 4, 2024, and October 3, 2025 [2]. - The complaint alleges that Skye's executives made materially false and misleading statements regarding the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Skye have until January 16, 2026, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm represents investors on a contingency fee basis, meaning they will only charge fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for recovering hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Points - A shareholder class action lawsuit has been filed against Skye Bioscience, Inc. alleging that the company made materially false and misleading statements regarding the effectiveness of nimacimab [1] - The lawsuit claims that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to misleading public statements by the defendants [1] - The lawsuit covers shareholders who purchased shares between November 4, 2024, and October 3, 2025, and experienced significant losses [2] Legal Information - The deadline for shareholders to ask the court to be appointed lead plaintiff in the case is January 16, 2026 [3] - Holzer & Holzer, LLC is the law firm representing the shareholders, known for its vigorous representation in securities litigation [3]

Core Viewpoint - A securities class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of California on behalf of all individuals or entities that purchased Skye securities between November 4, 2024, and October 3, 2025 [1]. - The complaint alleges that the defendants overstated the effectiveness and prospects of nimacimab, leading to materially false and misleading public statements [2]. Group 2: Investor Information - Investors who acquired shares of Skye are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on January 16, 2026 [3].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors about the effectiveness and prospects of its lead drug candidate, nimacimab [1][2]. Company Overview - Skye Bioscience, Inc. is a clinical stage biopharmaceutical company focused on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases [1]. Allegations - The lawsuit claims that during the class period, Skye failed to disclose that nimacimab was less effective than previously stated, leading to overstated clinical, regulatory, and commercial prospects [2]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint of weight loss compared to placebo in a Phase 2a study, resulting in a significant stock price drop of $2.85 per share, or 60%, closing at $1.90 per share [3]. Legal Proceedings - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [4]. - The representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur fees or expenses [5].

Financial Data and Key Metrics Changes - The company ended Q3 2025 with cash and cash equivalents and short-term investments totaling $35.3 million, which is expected to fund operations and key clinical milestones into 2027 [3] - R&D expenses for Q3 2025 were $9.4 million, an increase from $4.9 million in Q3 2024, primarily due to contract manufacturing and clinical trial costs [4] - General and administrative expenses decreased to $3.9 million in Q3 2025 from $4.6 million in Q3 2024 [4] - The net loss for Q3 2025 was $12.8 million, compared to $3.9 million for the same period in 2024 [5] Business Line Data and Key Metrics Changes - The focus remains on the clinical development of Nemesimab, with insights from the CBON study shaping future studies [6][7] - The combination of Nemesimab and semaglutide showed a 3% additional weight loss at 26 weeks compared to semaglutide alone, indicating a nearly 30% improvement [9] - The combination therapy also improved the lean-to-fat mass ratio significantly, with a p-value of 0.0126 [9] Market Data and Key Metrics Changes - The company is addressing the competitive landscape by focusing on the scalability and long-term market penetration of Nemesimab [8][13] - The safety profile of Nemesimab has been positive, with no neuropsychiatric signals observed, which is crucial for market acceptance [17] Company Strategy and Development Direction - The company is committed to refining the dose of Nemesimab to unlock its true efficacy and capture its therapeutic potential [10][12] - There is a strong emphasis on manufacturing and cost management to ensure competitiveness in the obesity market [14] - The company plans to present new preclinical and clinical data at major scientific conferences in 2026, indicating a proactive approach to investor relations and market engagement [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical data and the potential for Nemesimab, highlighting the importance of translating insights into actionable strategies [19] - The focus for the next 90 days includes generating a more complete picture of Nemesimab's potential and refining the dosing strategy [17] Other Important Information - The company completed enrollment for a 26-week extension study with 43 patients, which is expected to provide insights into the long-term efficacy of Nemesimab [11] - The company is exploring both induction and maintenance therapy opportunities for Nemesimab, recognizing the commercial potential in both areas [52][59] Q&A Session Summary Question: Insights on weight loss and exposure from the trial - Management indicated that the observed concentrations at the 200 mg dose did not achieve expected efficacy due to underdosing, and further analysis is ongoing [21][23] Question: Concerns about the 26-week extension data with 43 patients - Management acknowledged the smaller patient number but expressed confidence in the ability to see clear separation in results, especially given the strong initial data [26][28] Question: Regulatory considerations for monotherapy approval - It was confirmed that monotherapy approval would be necessary for maintenance therapy, and discussions with regulatory agencies are ongoing [32][34] Question: Feedback from KOLs following the CB1 phase 2A data - Positive feedback was received regarding the combination data and the potential for a differentiated mechanism of action without neuropsychiatric adverse events [60][64]